EGFR and non-small cell lung carcinoma: Among patients with NSCLC harboring the EGFR T790M mutation who have been previously treated with first- or second-generation EGFR-TKI, a phase 3 trial (AURA 3) demonstrated striking efficacy of osimertinib compared to intravenous pemetrexed plus either carboplatin or cisplatine [4].